C-squared Pharma

Activities: Ingredients

Trending Articles

  1. Ultra-high potency and its impact on pharmaceutical outsourcing This article explores the emerging distinction between high and ultra-high potency APIs, highlighting the implications for pharmaceutical outsourcing and risk management in an...
  2. Clarivate releases Drugs to Watch 2026 report The report features 11 breakthrough therapies shaping obesity, women's health, rare disease care and oncology innovation from companies such as Eli Lilly and GSK
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    The last word on mRNA analysis: trends, challenges and what’s next Advances in LC–MS, automation and data integration are transforming mRNA analysis from niche experimentation into a cornerstone of regulated CMC workflows, writes Matt Boag,...
  4. LYOVAC® ECO Mode: making pharmaceutical freeze-drying leaner and greener Following the recent announcement that GEA Lyophil has received third-party certification for the energy-saving credentials of its innovative algorithm for freeze-drying...
  5. PCI Pharma Services PCI Pharma Services: Your bridge between life-changing therapies and patients.

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

Related Content

Manufacturing

C2 PHARMA receives CEP approval for Oxybuprocaine hydrochloride

C2 PHARMA proudly announces the approval of a Certificate of Suitability (CEP) for Oxybuprocaine hydrochloride by the European Directorate for the Quality of Medicines and Health Care (EDQM)
Manufacturing

C2 PHARMA marks 10 years at CPHI Milan with expanded ophthalmic APIs

The complany is ready to showcase its expanding ophthalmic API portfolio and global regulatory filings, featuring Naphazoline Hydrochloride and Tropicamide
Ingredients

C2 PHARMA expands ophthalmic API portfolio with Naphazoline Hydrochloride launch

C2 PHARMA, the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the launch of its latest API, Naphazoline Hydrochloride
Regulatory

C2 Pharma's Tropicamide receives CEP from the European Directorate

The CEP approval of the ophthalmic drug allows C2 Pharma to distribute Tropicamide globally
Ingredients

C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs
Ingredients

C2 Pharma to participate in DCAT Week 2024

The C2 PHARMA team will be located in the Benjamin hotel in Suite 2202
Ingredients

C2 PHARMA receives DMF approval in China for pilocarpine nitrate

C2 PHARMA announces the approval of a C-DMF for pilocarpine nitrate — granted on 30 October 2023 — an API manufactured by our Brazilian partner Anidro do Brasil
Subscribe now